News

Proceeds Support Advancement of Lead Product Candidates GFB-887 and GFB-024 Through Three Clinical Proof-of-Concept Readouts Oversubscribed Round Includes Public Healthcare Funds June 30, 2020 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the closing […]

June 18, 2020, Shanghai, China Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301), the first Phase III trial with dorzagliatin. Dorzagliatin is a first-in-class glucokinase activator administered orally, twice daily. […]

Montpellier, France, June 8, 2020 – On June 4, 2020, Professor Boris GUIU and his team at Montpellier University Hospital (France) successfully treated a 56-year-old patient with liver tumor using Quantum Surgical’s medical robot. Quantum Surgical, an innovative surgical robotic company founded in 2017, developed its robot in record time thanks to a highly talented […]

NEW YORK and HONG KONG, May 21, 2020 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading global life science investment group, has announced that it led three investments in the U.S. — two medtech and one telehealth — in April, 2020 amidst the COVID-19 pandemic. Each of the three companies is a commercial-stage leading innovator re-setting the standard of care […]

Proceeds will enable the company to meet growing demand for its automated microbial detection platform, currently used by a majority of the top 20 global biopharmaceutical companies, and support new product development for pandemic response. Global investor syndicate is led by Ally Bridge Group, joined by Endeavour Vision, and existing investors including Bain Capital Life […]

May 20, 2020 06:00 ET | Source: Atea Pharmaceuticals, Inc. Proceeds to support the clinical development of Atea’s oral, direct acting antiviral medicine for COVID-19, in addition to advancing its diverse pipeline of treatments for viral diseases Investigational new drug application cleared by U.S. Food and Drug Administration to start Phase 2 study of AT-527, Atea’s oral purine […]

MENLO PARK, Calif. — (BUSINESS WIRE) — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a $390 million Series D financing round. New investors including Public Sector Pension Investment Board (PSP Investments) and Canada Pension Plan Investment Board (CPP Investments), as well as two […]

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema, announces a $66 million financing led by Ally Bridge Group, a leading global life science investor. The financing also attracted new investors Adage Capital Management, HealthQuest Capital, Partner Fund Management, and Rock Springs Capital, as […]

San Francisco, April 30, 2020 — Virtual healthcare platform, Vida Health, announced today that it raised $25 million in new funding to meet the increased demand for mental and physical virtual care. The funding was led by Ally Bridge Group (ABG), a leading global life science investment firm. Returning investors include Yahoo! founder Jerry Yang’s […]

SAN FRANCISCO and SHANGHAI, Feb. 25, 2020 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Vir Biotechnology, Inc. (“Vir”) (Nasdaq: VIR) today announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of Coronavirus Disease 2019 (COVID-19), a […]